Literature DB >> 15501299

Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity.

Hilde Vermeirsch1, Rony M Nuydens, Philip L Salmon, Theo F Meert.   

Abstract

The primary aim of the study was to correlate pain development during bone cancer growth with objectively obtained tumor-induced changes in bone morphology. Additionally morphine sensitivity of this bone pain was evaluated. Mice were injected into the femur with osteolytic NCTC2472 cells, and behaviorally followed during a 3-week period. During the observation period increasing pain behavior was observed in tumor-bearing animals. Tumor mice exhibited spontaneous and movement-evoked lifting, the latter evoked through non-noxious palpation of the tumor. Limb use during forced ambulation on a rotarod decreased to substantial non-use of the affected limb by day 23. On day 23, micro-computer tomography scans of the tumor-bearing bones were evaluated for bone destruction. Different bone parameters indicative of osteolysis or fragmentation were significantly correlated with pain behavior. In a separate group of mice the effects of different morphine doses on pain behavior were evaluated on days 17 and 21 of tumor growth. Spontaneous lifting and movement-evoked lifting were sensitive to morphine treatment, although stress-induced analgesia due to repeated restraint might minimize movement-evoked lifting in mice. Limb use during forced ambulation was only slightly ameliorated by high morphine doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501299     DOI: 10.1016/j.pbb.2004.07.011

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  15 in total

1.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Cancer pain physiology.

Authors:  Sarah Falk; Kirsty Bannister; Anthony H Dickenson
Journal:  Br J Pain       Date:  2014-11

3.  Grid-climbing Behaviour as a Pain Measure for Cancer-induced Bone Pain and Neuropathic Pain.

Authors:  Sarah Falk; Simone Gallego-Pedersen; Nicolas C Petersen
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 4.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

5.  Intrathecal substance P-saporin in the dog: efficacy in bone cancer pain.

Authors:  Dorothy Cimino Brown; Kimberly Agnello
Journal:  Anesthesiology       Date:  2013-11       Impact factor: 7.892

6.  Early diagnosis of orthopedic implant failure using macromolecular imaging agents.

Authors:  Ke Ren; Anand Dusad; Yijia Zhang; P Edward Purdue; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Dong Wang
Journal:  Pharm Res       Date:  2014-03-04       Impact factor: 4.200

7.  Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant.

Authors:  Anand Dusad; Michael J Duryee; Anita T Shaw; Lynell W Klassen; Daniel R Anderson; Dong Wang; Ke Ren; Ellen M Gravallese; James R O'Dell; Ted R Mikuls; Geoffrey M Thiele
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

8.  Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer.

Authors:  Xianzhu Ke; Wen Lin; Xiaokang Li; Hailiang Wang; Xin Xiao; Zheng Guo
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

9.  A multiparameter approach to monitor disease activity in collagen-induced arthritis.

Authors:  Sylvie Seeuws; Peggy Jacques; Jens Van Praet; Michael Drennan; Julie Coudenys; Tine Decruy; Ellen Deschepper; Lien Lepescheux; Philippe Pujuguet; Line Oste; Nick Vandeghinste; Reginald Brys; Gust Verbruggen; Dirk Elewaut
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

10.  A Study on the Mechanism of Cinobufagin in the Treatment of Paw Cancer Pain by Modulating Local β -Endorphin Expression In Vivo.

Authors:  Tao Chen; Wei Hu; Haibo He; Zipeng Gong; Jing Wang; Xueqin Yu; Ting Ai; Ling Zhan
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.